Sponsored satellite symposia
Stemline. A Menarini Group
|
Thursday 9 November 2023 – 18:00-19:30 Current and upcoming treatment strategies after CDK4/6 inhibitors for patients with ER+/HER2- advanced breast cancer |
|||||
|
|
|
||||
|
18:00-18:10 |
Welcome and introduction |
Ahmad Awada, BE |
|||
|
18:10-18:40 |
The current and future treatment landscape for ER+/HER2- mBC |
Ahmad Awada, BE |
|||
|
18:40-19:00 |
Emerging biomarkers in breast cancer: Implementing liquid biopsy ESR1 mutation testing |
Fredrik Marme, DE |
|||
|
19:00-19:10 |
Key takeaways |
Ahmad Awada, BE |
|||
|
19:10-19:30 |
Discussion |
All |
|||
|
|
|
|
|
||
|
|
Symposium faculty |
||||
Daiichi Sankyo/AstraZeneca
|
Friday 10 November 2023 – 18:00-19:30 Connecting the dots with antibody-drug conjugates (ADCs): Integrating patient experiences and recent data in metastatic breast cancer (mBC) |
|||||
|
|
|
||||
|
18:00-18:10 |
Welcome and introduction |
Sofia Braga, PT |
|||
|
18:10-18:25 |
Linking data with ADCs into clinical practice: |
Sofia Braga, PT |
|||
|
18:25-18:40 |
Interpreting adverse events associated with ADCs: How can we optimise safety in mBC? |
Santiago Escrivá-de-Romaní, ES |
|||
|
18:40-18:55 |
Putting patients’ quality of life first: What can we do to improve? |
Peter Fasching, DE |
|||
|
18:55-19:25 |
Panel discussion |
Panel discussion |
|||
|
19:25-19:30 |
Wrap up and close |
All faculty |
|||
|
|
|
|
|
||
|
|
Symposium faculty |
||||